Moderna 2026 Q3 Earnings Call
Review the key takeaways and the transcript of this earnings call.
- Moderna reported 3rd quarter 2026 revenue of $1.3 billion, up 29% year over year, and net income of $162 million, an improvement of $362 million compared with last year.
- Diluted earnings per share was $0.38, compared with a loss per share of $0.51 last year.
- Cash and investments were $8 billion at quarter-end, up from $6.9 billion at the end of the second quarter, including $2.6 billion of net proceeds from the convertible note and cap call transaction.
- Cost of sales was $318 million, or 24% of revenue; R&D expenses were $583 million, down 27% year over year; and SG&A expenses were $282 million, up 5%.
- Year-to-date revenue was $1.8 billion, including $900 million internationally, already $200 million ahead of full-year 2025 international revenue.
- The U.S. FDA approved Emfluciva, Moderna's 5th approved product and the first mRNA-based influenza vaccine to reach the market; Canada approved Emfluciva and EmcoFlu, the local brand name for mCOMBRIAX.
- In the Phase III INTerpath-001 trial in resected Stage IIB through IV melanoma, intismeran plus pembrolizumab reduced the risk of recurrence or death by 42% versus pembrolizumab alone; the hazard ratio was 0.58 and p-value below 0.001.
- At 2 years, recurrence-free survival was 82.2% with the combination and 70% with pembrolizumab alone; a modified intent-to-treat analysis showed a 49% reduction in the risk of recurrence or death and 2-year recurrence-free survival of 84.2% versus 70.4%.
- The melanoma combination was generally well tolerated; pembrolizumab-associated adverse events of interest occurred in 36% of combination patients and 35% of patients receiving pembrolizumab alone.
- In a Phase I pancreatic cancer study, neoantigen-specific T-cell responses were generated in all 19 evaluable patients.
- Moderna raised $3 billion through a 0% convertible note issuance and received approximately $2.6 billion in net proceeds after the purchase of cap calls and fees.
- The Ebola vaccine candidate mRNA-1469, developed with CEPI, was selected to advance into Phase II/III following a recommendation from the WHO Technical Advisory Group.
STOCKNOW INSIGHTS
Continue with outlook and guidance.
Log in to unlock executive comments and Q&A highlights.
Log in for the full summaryStockNow uses AI to translate and summarize earnings calls. Accuracy and completeness are not guaranteed.
Transcript
Preview the first fifteen paragraphs, organized by speaker.
Good day, and thank you for standing by. Welcome to Moderna's third quarter 2026 conference call. At this time, all participants are in a listen-only mode. After the speaker's presentation, there will be a question-and-answer session. To ask a question during the session, you will need to press star one on your telephone. You will then hear an automated message advising your hand is raised. To withdraw your question, please press star one again. Please be advised today's conference is being recorded. I would now like to hand the conference over to your speaker today, Lavina Talukdar.
Please go ahead. Thank you, Kevin.
Good morning, everyone, and thank you for joining us on today's call to discuss Moderna's third quarter 2026 financial results and business updates. You can access the press release issued this morning, as well as the slides that we will be reviewing, by going to the Investors section of our website. On today's call are Stéphane Bancel, our Chief Executive Officer, Stephen Hoge, our President, Jamey Mock, our Chief Financial Officer, and David Berman, our Chief Development Officer. Before we begin, please note that this call will include forward-looking statements made pursuant to the Safe Harbor provisions of the Private Securities Litigation Reform Act of 1995. Please see slide two of the accompanying presentation and our SEC filings for important risk factors that could cause our actual performance and results to differ materially from those expressed or implied in these forward-looking statements.
With that, I will turn the call over to Stéphane.
Thank you, Lavina. Good morning or good afternoon, everyone. Thank you for joining us. I will start today with a review of third quarter. Jamey will then cover our financial results and outlook, followed by Stephen with our current business updates in infectious disease. David will then review our clinical progress in oncology and rare diseases, and I will come back quickly for a close on our key value drivers before Q&A. The Moderna team delivered a great third quarter, generating $1.3 billion in revenues, representing 29% growth year-over-year. Importantly, this strong commercial performance translated into $200 million in net income for the quarter. We also ended the quarter with a strong balance sheet, with $8 billion in cash and investments, reflecting a combination of solid operational and commercial execution, along with a highly successful convertible debt financing.
We continue to demonstrate financial discipline across the company, reducing cash cost by 10% compared to the third quarter of last year. Together, these strong results underscore our ability to deliver strong commercial performance while maintaining financial discipline and strengthening our financial position. During the quarter, we achieved several important milestones across our pipeline and our business. U.S. FDA approval of mFLUSIVA, making Moderna's fifth approved product and the first mRNA-based influenza vaccine to reach the market. In Canada, we secured approvals of both mFLUSIVA and mCOFLU yesterday, the local brand name for mCOMBRIAX, further expanding our respiratory portfolio internationally. In oncology, we are very proud to present positive phase III data for intismeran autogene, our individualized cancer therapy being developed in partnership with Merck. The result demonstrated a significant clinical benefit, with a 42% reduction in the risk of recurrence or death in patients with resected melanoma.
An additional analysis suggesting an even greater benefit of 49% reduction in the risk of recurrence or death in patients who received at least one dose of intismeran as planned. Importantly, this marks the first combination immunotherapy regimen to demonstrate additional benefit over KEYTRUDA alone in the adjuvant melanoma setting, representing a significant milestone for melanoma patients and their families around the world. David will discuss these results in greater details. We also took an important step to further strengthen our financial position. During the quarter, we raised $3 billion through a 0% convertible note debt, securing long-term capital on highly attractive terms. After accounting for the purchase of capped calls designed to mitigate potential future dilution and fees, we raised approximately $2.6 billion in net proceeds.
This financing strengths our ability to invest in the growth of our oncology business, a key strategic priority for Moderna as we approach candidate important clinical milestone. In global health, our Ebola vaccine candidate, mRNA-1469, developed in collaboration with CEPI, was selected to advance into phase II/III following a recommendation from the WHO Technical Advisory Group. I am extremely proud of the performance delivered by the team in Q3. Strong sales growth, profitability, approval, and quick launch of flu in the U.S., intismeran positive phase III, and the convert debt financing. I am also very pleased and happy to welcome back Juan Andres to Moderna executive committee. Many of you will remember Juan for his previous time at Moderna, where he played a critical role in building and scaling our global manufacturing network during the pandemic. He also led the scale-out of individualized manufacturing for intismeran autogene.
He knows our company, our technology, and our culture extremely well. As we enter this next phase of Moderna's growth with an expanded commercial portfolio and important opportunities ahead in oncology, having Juan back on the team will be invaluable. I am personally very excited to be working with him again, and I know the entire Moderna team is delighted to welcome him back. With that, I turn to Jamey.
Thanks, Stéphane, and hello, everyone. Today, I will begin with a review of our third quarter financial performance, followed by an update on our 2026 financial framework. Let me start with our commercial performance on slide eight. We delivered a strong third quarter, with revenue of $1.3 billion, bringing our year-to-date revenue to $1.8 billion. Our geographic mix for the quarter was approximately 60% U.S. and 40% international. Both the U.S. and international markets delivered stronger-than-expected revenue in 3Q, driven by a mix of increased demand, operational execution, and timing of shipments between the third and fourth quarters. As mentioned in prior calls, we forecasted two primary growth drivers in 2026: increased mNEXSPIKE adoption and growth in our strategic partnerships in the U.K., Canada, and Australia.
In the U.S., while the vaccination season is still ongoing, we have seen increased uptake of mNEXSPIKE, and vaccination rates have been relatively stable versus the prior year. Internationally, our teams have executed well, particularly in the U.K. and Canada. Year-to-date international revenue of $900 million is already $200 million ahead of the full year we delivered in 2025. Based on the strong start to the season, combined with the visibility we have into the fourth quarter, we are increasing our full-year revenue framework to a range of 15%-25% growth, which exceeds our prior framework of up to 10% growth. We continue to expect an approximately even split between U.S. and international revenue for the full year. Now let me turn to our third-quarter financial performance on slide nine.
As I just mentioned, total revenue was $1.3 billion for the quarter, up 29% from last year, primarily driven by higher COVID sales. Cost of sales for the quarter was $318 million, representing 24% of total revenue for the quarter. This was a 54% increase in our cost of sales from Q3 last year, primarily driven by higher product sales volume and other manufacturing-related costs. We remain on track to drive significant gross margin improvements in 2026, excluding the $900 million litigation charge. R&D expenses for the quarter were $583 million, down 27% from last year, driven by completion and wind-down of studies in our infectious disease portfolio, as well as efficiency gains across the organization. SG&A expenses for the quarter were $282 million, a 5% increase year-over-year. We continue to maintain cost discipline across the organization while investing for growth.
Our income tax provision was immaterial in both periods. Net income for the quarter was $162 million, an improvement of $362 million compared to last year. Diluted earnings per share was $0.38, compared to a loss per share of $0.51 last year. We ended the quarter with cash and investments of $8 billion, up from $6.9 billion at the end of the second quarter. The increase was primarily driven by $2.6 billion of net proceeds from our convertible note issuance and capped call transaction, partially offset by a $950 million litigation settlement payment, as well as the seasonal impact to working capital. Now let's turn to our financial framework for 2026.
For total revenue, as I mentioned in my earlier remarks, we are improving our revenue outlook to a range of 15%-25% growth, which exceeds our prior framework of up to 10% growth. Cost of sales is unchanged at $1.7 billion, which includes $0.9 billion of expense related to the previously announced litigation settlement charge. We are lowering our R&D expense by $200 million to $2.7 billion due to further wind-down of studies and continued operational efficiencies. SG&A expenses are still expected to be approximately $1 billion, flat versus the prior year. Similar to last year, we expect higher SG&A expenses in the fourth quarter, primarily due to commercial-related activity. In aggregate, excluding the $0.9 billion litigation charge, we are expecting total GAAP operating expenses of $4.5 billion and $3.8 billion of cash costs, which excludes stock-based compensation, depreciation, and amortization.
Each reflect a $200 million improvement compared to our previous framework. We expect taxes to be negligible in 2026, and we are lowering our capital expenditure estimate to $200 million from our previous range of $200 million-$300 million. Cash and investments are now projected to be between $8.1 billion and $8.3 billion at the end of 2026. Excluding the $2.6 billion net proceeds from the convertible note and capped call transaction, our cash projection would be $5.5 billion-$5.7 billion, which is an improvement from our previous framework of $4.7 billion-$5.2 billion. The increase in our cash projection is due to our improved revenue outlook and reductions in both our cash cost and CapEx projections. Our cash cost framework does not assume any additional drawdown from our remaining $0.9 billion undrawn credit facility.
FULL TRANSCRIPT
Continue the full translated transcript in StockNow.
Log in to unlock every statement, the English original, and speaker-by-speaker history.
Log in for the full transcriptCall participants
19 people spoke on this call — only 2 are shown here.
PARTICIPANT LIST
View participant details in StockNow.
Log in to see executives and analysts, their roles, and complete speaking history.
Log in to view all participantsKeep exploring
